Molecular target identification in kidney disease across disciplines and continents
Learn how researchers at University Michigan have used a precision medicine strategy to attack chronic kidney disease —identifying new biomarkers for disease progression, and targets for drug discovery projects to develop new therapeutics.
More than 20 million Americans — 1 in 10 adults — have some level of chronic kidney disease, making the search for better diagnostic tools and new therapies a high priority for researchers.
The current biomarkers do a poor job in predicting disease progression, and patients have few options beyond burdensome dialysis or kidney transplant. Frances Collins, Director NIH, recently highlighted the importance of Matthias’s research in a recent blog post.
About the Speaker
The overarching goal of Kretzler’s research is to define renal disease in mechanistic terms and to use this knowledge for targeted therapeutic interventions. To reach this goal, Kretzler has developed a translational research pipeline centered on integrated systems biology analysis of glomerular disease. He is the principal investigator of the U54 Nephrotic Syndrome Research Network (Neptune) in the Rare Disease Clinical Research Network II, the Data Coordinating Center for the UM1 CureGN network, and the Director of the Applied Systems Biology Core at the O’Brien Renal Center at University of Michigan. Kretlzer has 20 years of experience in integration of bioinformatics, molecular and clinical approaches in more than 150 collaborative studies on molecular analysis of renal disease.